Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Chlamydia Trachomatis | Study protocol

Evaluating the diagnosis and treatment of Chlamydia trachomatis and Neisseria gonorrhoeae in pregnant women to prevent adverse neonatal consequences in Gaborone, Botswana: protocol for the Maduo study

Authors: Adriane Wynn, Aamirah Mussa, Rebecca Ryan, Emily Hansman, Selebaleng Simon, Bame Bame, Badani Moreri-Ntshabele, Doreen Ramogola-Masire, Jeffrey D. Klausner, Chelsea Morroni

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are extremely common sexually transmitted infections (STIs) that are associated with adverse birth and neonatal outcomes, and the risk of vertical transmission of CT and NG during delivery is high. The majority of CT and NG infections are asymptomatic and missed by the standard of care in most countries (treatment based on symptoms). Thus, it is likely that missed maternal CT and NG infections contribute to preventable adverse health outcomes among women and children globally. This study aims to assess the effectiveness of CT and NG testing for asymptomatic pregnant women to prevent adverse neonatal outcomes, understand the inflammatory response linking CT and NG infections to adverse neonatal outcomes, and conduct an economic analysis of the CT and NG testing intervention.

Methods

The Maduo (“results” in Setswana) is a prospective, cluster-controlled trial in Gaborone, Botswana to compare a near point-of-care CT and NG testing and treatment intervention implemented in “study clinics” with standard antenatal care (World Health Organization-endorsed “syndromic management” strategy based on signs and symptoms without laboratory confirmation) implemented in “standard of care clinics” among asymptomatic pregnant women. The primary outcome is vertical transmission of CT/NG infection. Secondary outcomes include preterm birth (delivery < 37 completed weeks of gestation) and/or low birth weight (< 2500 g). The trial will also evaluate immunological and inflammatory markers of adverse neonatal outcomes, as well as the costs and cost-effectiveness of the intervention compared with standard care.

Discussion

The Maduo study will improve our understanding of the effectiveness and cost-effectiveness of CT and NG testing among asymptomatic pregnant women. It will also increase knowledge about the CT/NG-related immune responses that might drive adverse neonatal outcomes. Further, results from this study could encourage expansion of STI testing during antenatal care in low resource settings and improve maternal and neonatal health globally.
Trial registration: This trial is registered with ClinicalTrials.gov (Identifier NCT04955717, First posted: July 9, 2021)).
Literature
1.
Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97(8):548–62.PubMedPubMedCentralCrossRef
2.
Newman L, Rowley J, Vander Hoorn S, Wijesooriya N, Unemo M, Low N, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS ONE. 2015;10(12):e0143304.PubMedPubMedCentralCrossRef
3.
Kenyon C, Buyze J, Colebunders R. Classification of incidence and prevalence of certain sexually transmitted infections by world regions. Int J Infect Dis. 2014;18:73–80.PubMedCrossRef
4.
Lin JS, Donegan SP, Heeren TC, Greenberg M, Flaherty EE, Haivanis R, et al. Transmission of Chlamydia trachomatis and Neisseria gonorrhoeae among men with urethritis and their female sex partners. J Infect Dis. 1998;178(6):1707–12.PubMedCrossRef
5.
European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ. 1992;304:809–13.CrossRef
6.
Blanc AK. The effect of power in sexual relationships on sexual and reproductive health: an examination of the evidence. Stud Fam Plann. 2001;32(3):189–213.PubMedCrossRef
7.
Workowski K, Berman S. Sexually transmitted diseases treatment guidelines, 2010. Centers Dis Control Prevent Morbid Mortal Wkly Rep Recommend Rep. 2010;59(RR-12):1–110.
8.
Peipert J. Clinical practice.Genital chlamydial infections. N Eng J Med. 2003;349(25):2424–30.CrossRef
9.
10.
Kularatne RS, Niit R, Rowley J, Kufa-Chakezha T, Peters RPH, Taylor MM, et al. Adult gonorrhea, chlamydia and syphilis prevalence, incidence, treatment and syndromic case reporting in South Africa: estimates using the Spectrum-STI model, 1990–2017. PLoS ONE. 2018;13(10):e0205863.PubMedPubMedCentralCrossRef
11.
Joseph Davey DL, Shull HI, Billings JD, Wang D, Adachi K, Klausner JD. Prevalence of curable sexually transmitted infections in pregnant women in low- and middle-income countries from 2010 to 2015. Sex Transm Dis. 2016;43(7):450–8.PubMedCrossRef
12.
Carveth-Johnson T, Dunin De Skrzynno S, Wynn A, Moshashane N, Ramontshonyana K, Lebelonyane R, et al. Integrating STI testing and treatment with routine HIV care in Gaborone. Botswana Sex Transm Dis. 2021;48:887–94.PubMedCrossRef
13.
Vallely AJ, Pomat WS, Homer C, Guy R, Luchters S, Mola GDL, et al. Point-of-care testing and treatment of sexually transmitted infections to improve birth outcomes in high-burden, low-income settings: Study protocol for a cluster randomized crossover trial (the WANTAIM Trial, Papua New Guinea). Wellcome Open Res. 2019;4:53.PubMedPubMedCentralCrossRef
14.
Mullick S. Sexually transmitted infections in pregnancy: prevalence, impact on pregnancy outcomes, and approach to treatment in developing countries. Sex Transm Infect. 2005;81(4):294–302.PubMedPubMedCentralCrossRef
15.
Rours G, Duijts L, Moll H, Grends L, de Groot R, Jaddoe V, et al. Chlamydia trachomatis infection during pregnancy associated with preterm delivery: a population-based prospective cohort study. Eur J Epidemiol. 2011;26(6):493–502.PubMedPubMedCentralCrossRef
16.
Elliott B, Brunham RC, Laga M, Piot P, Ndinya-Achola JO, Maitha G, et al. Maternal gonococcal infection as a preventable risk factor for low birth weight. J Infect Dis. 1990;161(3):531–6.PubMedCrossRef
17.
Silva M, Florencio G, Gabiatti J, Amaral R, Eleuterio J, Goncalves A. Perinatal morbidity and mortality associated with chlamydial infection: a meta-analysis study. Braz J Infect Dis. 2011;15(6):533–9.PubMedCrossRef
18.
Folger AT. Maternal Chlamydia trachomatis infections and preterm birth: the impact of early detection and eradication during pregnancy. J Matern Child Health. 2014;18(8):1795–802.CrossRef
19.
Kupka R, Kassaye T, Saathoff E, Hertzmark E, Msamanga GI, Fawzi WW. Predictors of stillbirth among HIV-infected Tanzanian women. Acta Obstet Gynecol Scand. 2009;88(5):584–92.PubMedPubMedCentralCrossRef
20.
Schachter JGM, Sweet RL, Holt J, Jordan C, Bishop E. Prospective study of perinatal transmission of Chlamydia trachomatis. JAMA. 1986;255(24):3374–7.PubMedCrossRef
21.
Hammerschlag M, Chandler J, Alexander E, English M, Koutsky L. Longitudinal studies on chlamydial infections in the first year of life. Pediatr Infect Dis J. 1982;1(6):395.CrossRef
22.
Laga M, Plummer F, Nzanze H, et al. Epidemiology of ophthalmia neonatorum in Kenya. Lancet. 1986;2:1145–9.PubMedCrossRef
23.
Vallely LM, Egli-Gany D, Wand H, Pomat WS, Homer CSE, Guy R, et al. Adverse pregnancy and neonatal outcomes associated with Neisseria gonorrhoeae: systematic review and meta-analysis. Sex Transm Infect. 2021;97(2):104–11.PubMedCrossRef
24.
Mudau M, Kojima N, Peters R, Feucht U, De Vos L, Olivier D, et al. Postpartum prevalence and Incidence of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis among Human Immunodeficiency Virus-Infected women in South Africa and the transmission of maternal infections to newborns. In submission. 2018.
25.
Adachi K, Xu J, Yeganeh N, Camarca M, Morgado MG, Watts DH, et al. Combined evaluation of sexually transmitted infections in HIV-infected pregnant women and infant HIV transmission. PLoS ONE. 2018;13(1):e0189851.PubMedPubMedCentralCrossRef
26.
Adachi K, Klausner JD, Bristow CC, Xu J, Ank B, Morgado MG, et al. Chlamydia and Gonorrhea in HIV-infected pregnant women and infant HIV transmission. Sex Transm Dis. 2015;42(10):554–65.PubMedPubMedCentralCrossRef
27.
Zar HJ, Van Dyk A, Yeats JK, Hanslo D. Chlamydia trachomatis lower respiratory tract infection in infants. Ann Trop Paediatr. 1999;19(1):9–13.PubMedCrossRef
28.
Adachi KN-SK, Klausner JD. Chlamydia Trachomatis infection in pregnancy: the global challenge of preventing adverse pregnancy and neonatal outcomes in Sub-Saharan Africa and Asia. BioMed Res Int. 2016;2016:1–21.CrossRef
29.
Mayer KH, Venkatesh KK. Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition. Am J Reprod Immunol (New York, NY 1989). 2011;65(3):308–16.CrossRef
30.
Osuji FN, Onyenekwe CC, Ahaneku JE, Ukibe NR. The effects of highly active antiretroviral therapy on the serum levels of pro-inflammatory and anti-inflammatory cytokines in HIV infected subjects. J Biomed Sci. 2018;25(1):88.PubMedPubMedCentralCrossRef
31.
32.
Presicce P, Park CW, Senthamaraikannan P, Bhattacharyya S, Jackson C, Kong F, et al. IL-1 signaling mediates intrauterine inflammation and chorio-decidua neutrophil recruitment and activation. JCI Insight. 2018;3(6).
33.
So T, Ito A, Sato T, Mori Y, Hirakawa S. Tumor necrosis factor-alpha stimulates the biosynthesis of matrix metalloproteinases and plasminogen activator in cultured human chorionic cells. Biol Reprod. 1992;46(5):772–8.PubMedCrossRef
34.
Fortunato SJ, Menon R, Lombardi SJ. Role of tumor necrosis factor-alpha in the premature rupture of membranes and preterm labor pathways. Am J Obstet Gynecol. 2002;187(5):1159–62.PubMedCrossRef
35.
Oner C, Schatz F, Kizilay G, Murk W, Buchwalder LF, Kayisli UA, et al. Progestin-inflammatory cytokine interactions affect matrix metalloproteinase-1 and -3 expression in term decidual cells: implications for treatment of chorioamnionitis-induced preterm delivery. J Clin Endocrinol Metab. 2008;93(1):252–9.PubMedCrossRef
36.
Adachi KN, Nielsen-Saines K, Klausner JD. Chlamydia trachomatis screening and treatment in pregnancy to reduce adverse pregnancy and neonatal outcomes: a review. Front Public Health. 2021;9(561).
37.
Baud D, Greub G. Intracellular bacteria and adverse pregnancy outcomes. Clin Microbiol Infect. 2011;17(9):1312–22.PubMedCrossRef
38.
Baud D, Regan L, Greub G. Emerging role of Chlamydia and Chlamydia-like organisms in adverse pregnancy outcomes. Curr Opin Infect Dis. 2008;21(1):70–6.PubMedCrossRef
39.
Witkin SS, Neuer A, Giraldo P, Jeremias J, Tolbert V, Korneeva IL, et al. Chlamydia trachomatis infection, immunity, and pregnancy outcome. Infect Dis Obstet Gynecol. 1997;5(2):128–32.PubMedPubMedCentralCrossRef
40.
Locksmith G, Duff P. Infection, antibiotics, and preterm delivery. Semin Perinatol. 2001;25(5):295–309.PubMedCrossRef
41.
Markenson GR, Saade GR, Laurent LC, Heyborne KD, Coonrod DV, Schoen CN, et al. Performance of a proteomic preterm delivery predictor in a large independent prospective cohort. Am J Obstet Gynecol MFM. 2020;2(3):100140.PubMedCrossRef
42.
Glover AV, Manuck TA. Screening for spontaneous preterm birth and resultant therapies to reduce neonatal morbidity and mortality: a review. Semin Fetal Neonatal Med. 2018;23(2):126–32.PubMedCrossRef
43.
Lucaroni F, Morciano L, Rizzo G, Francesco DA, Buonuomo E, Palombi L, et al. Biomarkers for predicting spontaneous preterm birth: an umbrella systematic review. J Matern Fetal Neonatal Med. 2018;31(6):726–34.PubMedCrossRef
44.
Saade GR, Boggess KA, Sullivan SA, Markenson GR, Iams JD, Coonrod DV, et al. Development and validation of a spontaneous preterm delivery predictor in asymptomatic women. Am J Obstet Gynecol. 2016;214(5):633e1-e24.CrossRef
45.
Bastek JA, Elovitz MA. The role and challenges of biomarkers in spontaneous preterm birth and preeclampsia. Fertil Steril. 2013;99(4):1117–23.PubMedCrossRef
46.
Conde-Agudelo A, Papageorghiou AT, Kennedy SH, Villar J. Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis. BJOG. 2011;118(9):1042–54.PubMedCrossRef
47.
Wei SQ, Fraser W, Luo ZC. Inflammatory cytokines and spontaneous preterm birth in asymptomatic women: a systematic review. Obstet Gynecol. 2010;116(2 Pt 1):393–401.PubMedCrossRef
48.
Mayaud P, Mabey D. Approaches to the control of sexually transmitted infections in developing countries: old problems and modern challenges. Sex Transm Infect. 2004;80(3):174–82.PubMedPubMedCentralCrossRef
49.
50.
51.
Unemo M, Bradshaw CS, Hocking JS, de Vries HJC, Francis SC, Mabey D, et al. Sexually transmitted infections: challenges ahead. Lancet Infect Dis. 2017;17(8):e235–79.PubMedCrossRef
52.
Romoren M, Sundby J, Velauthapillai M, Rahman M, Klouman E, Hjortdahl P. Chlamydia and gonorrhoea in pregnant Batswana women: time to discard the syndromic approach? BMC Infect Dis. 2007;7:27.PubMedPubMedCentralCrossRef
53.
Romoren M, Velauthapillai M, Rahman M, Sundby J, Klouman E, Hjortdahl P. Trichomoniasis and bacterial vaginosis in pregnancy: inadequately managed with the syndromic approach. Bull World Health Organ. 2007;85(4):297–304.PubMedPubMedCentralCrossRef
54.
Romoren M, Rahman M, Sundby J, Hjortdahl P. Chlamydia and gonorrhoea in pregnancy: effectiveness of diagnosis and treatment in Botswana. Sex Transm Infect. 2004;80(5):395–400.PubMedPubMedCentralCrossRef
55.
Silveira MF, Ghanem KG, Erbelding EJ, Burke AE, Johnson HL, Singh RH, et al. Chlamydia trachomatis infection during pregnancy and the risk of preterm birth: a case–control study. Int J STD AIDS. 2009;20(7):465–9.PubMedCrossRef
56.
Garrett NJ, McGrath N, Mindel A. Advancing STI care in low/middle-income countries: has STI syndromic management reached its use-by date? Sex Transm Infect. 2017;93(1):4–5.PubMedCrossRef
57.
van Gemert C, Hellard M, Bradshaw CS, Fowkes FJI, Agius PA, Stoove M, et al. Syndromic management of sexually transmissible infections in resource-poor settings: a systematic review with meta-analysis of the abnormal vaginal discharge flowchart for Neisseria gonorrhoea and Chlamydia trachomatis. Sex Health. 2018;15(1):1–12.PubMedCrossRef
58.
Romoren M, Sundby J, Velauthapillai M, Rahman M, Klouman E, Hjortdahl P. Chlamydia and gonorrhoea in pregnant Batswana women: time to discard the syndromic approach? BMC Infect Dis. 2007;7(27).
59.
Medline A, Joseph Davey D, Klausner JD. Lost opportunity to save newborn lives: variable national antenatal screening policies for Neisseria gonorrhoeae and Chlamydia trachomatis. Int J STD AIDS. 2016;28(7):660–6.PubMedPubMedCentralCrossRef
60.
Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis. 2010;201(Supplement_2):S134–55.PubMedCrossRef
61.
Hook EW 3rd, Spitters C, Reichart CA, Neumann TM, Quinn TC. Use of cell culture and a rapid diagnostic assay for Chlamydia trachomatis screening. JAMA. 1994;272(11):867–70.PubMedCrossRef
62.
Stamm WE, Guinan ME, Johnson C, Starcher T, Holmes KK, McCormack WM. Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N Engl J Med. 1984;310(9):545–9.PubMedCrossRef
63.
Mlisana KNN, Werner L, Roberts L, van Loggerenberg F, Baxter C, Passmore JS, Grobler AC, Sturm AW, Williamson C, Ronacher K, Walzl G, Abdool Karim SS. Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. J Infect Dis. 2012;206:6–14.PubMedPubMedCentralCrossRef
64.
Iqbal SM, Kaul R. Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol (New York, NY: 1989). 2008;59(1):44–54.CrossRef
65.
Garrett NJ, Osman F, Maharaj B, Naicker N, Gibbs A, Norman E, et al. Beyond syndromic management: opportunities for diagnosis-based treatment of sexually transmitted infections in low- and middle-income countries. PLoS ONE. 2018;13(4):e0196209.PubMedPubMedCentralCrossRef
66.
Jasumback CL, Perry SH, Ness TE, Matsenjwa M, Masangane ZT, Mavimbela M, et al. Point-of-care testing to guide treatment and estimate risk factors for sexually transmitted infections in adolescents and young people with human immunodeficiency virus in Eswatini. Open Forum Infect Dis. 2020;7(3):ofaa052.PubMedPubMedCentralCrossRef
67.
Oakeshott P, Kerry S, Aghaizu A, Atherton H, Hay S, Taylor-Robinson D, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ. 2010;340:c1642.PubMedPubMedCentralCrossRef
68.
Peters R, Klausner J, Feucht U, Vos L, Medina-Marino A. Aetiologic testing compared with syndromic management for sexually transmitted infections in HIV-infected pregnant women in South Africa: a non-randomised prospective cohort study. BJOG. 2021;128(8):1335–42.PubMedCrossRef
69.
Workowski KABS. Sexually transmitted diseases treatment guidelines, 2010. Centers Dis Control Prevent Morbid Mortal Wkly Rep Recommend Rep. 2010;59(RR-2):1–110.
70.
Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, et al. Screening for Chlamydia and Gonorrhea: US preventive services task force recommendation statement. JAMA. 2021;326(10):949–56.PubMedCrossRef
71.
72.
Botswana MoH. Handbook of the Botswana 2016 Integrated HIV Clinical Care Guidelines. 2016.
73.
Botswana MoH. Botswana National HIV & AIDS Treatment Guidelines. 2012.
74.
Lawrie TA, Hofmeyr GJ, de Jager M, Berk M. Validation of the Edinburgh Postnatal Depression Scale on a cohort of South African women. South Afr Med J Suid-Afrikaanse tydskrif vir geneeskunde. 1998;88(10):1340–4.
75.
Seth P, Glenshaw M, Sabatier JH, Adams R, Du Preez V, DeLuca N, et al. AUDIT, AUDIT-C, and AUDIT-3: drinking patterns and screening for harmful, hazardous and dependent drinking in Katutura, Namibia. PLoS ONE. 2015;10(3):e0120850.PubMedPubMedCentralCrossRef
76.
Straus M. Measuring intrafamily conflict and violence: the conflict tactics (CT) scales. J Marriage Fam. 1979;41(1):75–88.CrossRef
77.
Hammerschlag MRRP, Gelling M, Tsumura N, Jule JE, Kutlin A. Use of polymerase chain reaction for the detection of Chlamydia trachomatis in ocular and nasopharyngeal specimens from infants with conjunctivitis. Pediatr Infect Dis J. 1997;16(3):293.PubMedCrossRef
78.
Yip PPCW, Yip KT, Que TL, Kwong NS, Ho CK. The use of polymerase chain reaction assay versus conventional methods in detecting neonatal chlamydial conjunctivitis. J Pediatr Ophthalmol Strabismus. 2008;45(4):234–9.PubMedCrossRef
79.
80.
Wynn A, Ramogola-Masire D, Gaolebale P, Moshashane N, Sickboy O, Duque S, et al. Prevalence and treatment outcomes of routine Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis testing during antenatal care, Gaborone. Botswana Sex Transm Infect. 2018;94(3):230–5.PubMedCrossRef
81.
Genuer R, Poggi J, Tuleau-Malot C. VSURF: an R package for variable selection using random forests. R J 2015;7(2):19–33.CrossRef
82.
Kojima N, Siebert JC, Maecker H, Rosenberg-Hasson Y, Leon SR, Vargas SK, et al. The application of cytokine expression assays to differentiate active from previously treated syphilis. J Infect Dis. 2020;222(4):690–4.PubMedPubMedCentralCrossRef
83.
Drummond M, Schulpher M, Claxton K, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. 2015.
Metadata
Title
Evaluating the diagnosis and treatment of Chlamydia trachomatis and Neisseria gonorrhoeae in pregnant women to prevent adverse neonatal consequences in Gaborone, Botswana: protocol for the Maduo study
Authors
Adriane Wynn
Aamirah Mussa
Rebecca Ryan
Emily Hansman
Selebaleng Simon
Bame Bame
Badani Moreri-Ntshabele
Doreen Ramogola-Masire
Jeffrey D. Klausner
Chelsea Morroni
Publication date
01-12-2022

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue

Research

Impact of intra-partum azithromycin on carriage of group A streptococcus in the Gambia: a posthoc analysis of a double-blind randomized placebo-controlled trial

Research

Clinical malaria incidence and health seeking pattern in geographically heterogeneous landscape of western Kenya

Research

Evaluating the clinical impact of routine whole genome sequencing in tuberculosis treatment decisions and the issue of isoniazid mono-resistance

Research article

Minnesota refugees diagnosed with tuberculosis disease, January 1993–August 2019

Research

Multi-marker approach using C-reactive protein, procalcitonin, neutrophil CD64 index for the prognosis of sepsis in intensive care unit: a retrospective cohort study

Research

Persistence of onchocerciasis in villages in Enugu and Ogun states in Nigeria following many rounds of mass distribution of ivermectin
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits